Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease
Brain and Behavior2017Vol. 8(1), pp. e00858–e00858
Citations Over TimeTop 16% of 2017 papers
Abstract
LRRK2 mutation carriers have an increased risk of non-skin cancer compared with iPD subjects, which was mainly driven by the association between harboring the mutation and breast cancer in women. The increased risk is likely independent of ethnicity.
Related Papers
- → High peroxidasin-like expression is a potential and independent prognostic biomarker in breast cancer(2019)28 cited
- → Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer(2018)3 cited
- → The American Cancer Society guidelines for breast screening with magnetic resonance imaging(2008)28 cited
- → A Prior Diagnosis of Breast Cancer is a Risk Factor for Breast Cancer in Brca1 and Brca2 Carriers(2014)15 cited
- → Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers(2019)10 cited